Hyperthermia combined with radiation for the treatment of locally advanced prostate cancer

Cancer

Volumn 117, Issue 3, 2011, Pages 510-516

  Hurwitz, Mark D ^a   Hansen, Jorgen L ^a   Prokopios Davos, Savina ^a   Manola, Judith ^b   Wang, Qian ^b   Bornstein, Bruce A ^a   Hynynen, Kullervo ^a,c,d   Kaplan, Irving D ^e  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

androgen deprivation; hyperthermia; prostate cancer; radiation therapy; thermometry

Indexed keywords

ANTIANDROGEN; GONADORELIN AGONIST; PROSTATE SPECIFIC ANTIGEN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FOLLOW UP; GLEASON SCORE; HUMAN; HYPERTHERMIC THERAPY; INTERMETHOD COMPARISON; MALE; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; SURVIVAL RATE; TRANSRECTAL ULTRASONOGRAPHY; TREATMENT FAILURE;

AGED; ANDROGEN ANTAGONISTS; COMBINED MODALITY THERAPY; FOLLOW-UP STUDIES; HUMANS; HYPERTHERMIA, INDUCED; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS;

EID: 79251488491     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25619     Document Type: Article

References (23)

1. Raaphorst GP, Szekely JG., Thermal enhancement of cellular radiation damage: a review of complementary and synergistic effects. Scanning Microsc. 1988; 2: 513-535.
2. Dewhirst MW, Vujaskovic Z, Jones E, Thrall D., Re-setting the biologic rationale for thermal therapy. Int J Hyperthermia. 2005; 21: 779-790.
3. Franceschi C., Cell proliferation, cell death and aging. Aging (Milano). 1989; 1: 3-15.
4. Fuller KJ, Issels RD, Slosman DO, Guillet JG, Soussi T, Polla BS., Cancer and the heat shock response. Eur J Cancer. 1994; 30A: 1884-1891.
5. Arya R, Mallik M, Lakhotia SC., Heat shock genesâintegrating cell survival and death. J Biosci. 2007; 32: 595-610.
6. Falk MH, Issels RD., Hyperthermia in oncology. Int J Hyperthermia. 2001; 17: 1-18.
7. Fosmire H, Hynynen K, Drach GW, Stea B, Swift P, Cassady JR., Feasibility and toxicity of transrectal ultrasound hyperthermia in the treatment of locally advanced adenocarcinoma of the prostate. Int J Radiat Oncol Biol Phys. 1993; 26: 253-259.
8. Algan O, Fosmire H, Hynynen K, et al. External beam radiotherapy and hyperthermia in the treatment of patients with locally advanced prostate carcinoma. Cancer. 2000; 89: 399-403.
9. Hurwitz MD, Kaplan ID, Hansen JL, et al. Hyperthermia combined with radiation in treatment of locally advanced prostate cancer is associated with a favourable toxicity profile. Int J Hyperthermia. 2005; 21: 649-656.
10. Pilepich MV, Krall JM, al-Sarraf M, et al. Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group. Urology. 1995; 45: 616-623.
11. Pilepich MV, Caplan R, Byhardt RW, et al. Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31. J Clin Oncol. 1997; 15: 1013-1021.
12. Bolla M, Gonzalez D, Warde P, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med. 1997; 337: 295-300.
13. Van Vulpen M, De Leeuw JR, Van Gellekom MP, et al. A prospective quality of life study in patients with locally advanced prostate cancer, treated with radiotherapy with or without regional or interstitial hyperthermia. Int J Hyperthermia. 2003; 19: 402-413.
14. Johannsen M, Gneveckow U, Taymoorian K, et al. Morbidity and quality of life during thermotherapy using magnetic nanoparticles in locally recurrent prostate cancer: results of a prospective phase I trial. Int J Hyperthermia. 2007; 23: 315-323.
15. Anscher MS, Samulski TV, Dodge R, Prosnitz LR, Dewhirst MW., Combined external beam irradiation and external regional hyperthermia for locally advanced adenocarcinoma of the prostate. Int J Radiat Oncol Biol Phys. 1997; 37: 1059-1065.
16. Deger S, Taymoorian K, Boehmer D, et al. Thermoradiotherapy using interstitial self-regulating thermoseeds: an intermediate analysis of a phase II trial. Eur Urol. 2004; 45: 574-580.
17. Tilly W, Gellermann J, Graf R, et al. Regional hyperthermia in conjunction with definitive radiotherapy against recurrent or locally advanced prostate cancer T3 pN0 M0. Strahlenther Onkol. 2005; 181: 35-41.
18. Maluta S, Dall'Oglio S, Romano M, et al. Conformal radiotherapy plus local hyperthermia in patients affected by locally advanced high risk prostate cancer: preliminary results of a prospective phase II study. Int J Hyperthermia. 2007; 23: 451-456.
19. Hanks GE, Pajak TF, Porter A, et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol. 2003; 21: 3972-3978.
20. D'Amico AV, Manola J, Loffredo M, Renshaw AA, DellaCroce A, Kantoff PW., Six-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA. 2004; 292: 821-827.
21. Denham JW, Steigler A, Lamb DS, et al. Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. Lancet Oncol. 2005; 6: 841-850.
22. Kuban DA, Tucker SL, Dong L, et al. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys. 2008; 70: 67-74.
23. Pollack A, Hanlon AL, Horwitz EM, Feigenberg SJ, Uzzo RG, Hanks GE., Prostate cancer radiotherapy dose response: an update of the Fox Chase experience. J Urol. 2004; 171: 1132-1136.